This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Fresenius Medical Care Withheld Information, Responsible For Deaths Of Dialysis Patients, Lawsuit Filed By Hagens Berman Claims

Hagens Berman Sobol Shapiro LLP, a law firm with extensive experience prosecuting negligence cases against the pharmaceutical industry, has filed a series of lawsuits against Fresenius Medical Care North America (FMC), a subsidiary of Fresenius Medical Care AG & Co. (NYSE: FMS), the largest hemodialysis company in the world, alleging the company failed to inform patients, the medical community or the Food and Drug Administration (FDA) of serious, life-threatening complications resulting from the use of its GranuFlo and NaturaLyte products in dialysis patients.

The plaintiffs in the suits claim that FMC’s products caused them to suffer heart attacks, strokes and brain aneurysms, risks the company was aware of far in advance of informing the FDA.

Steve W. Berman, managing partner of Hagens Berman and the attorney representing more than 30 alleged victims, expressed outrage at FMC’s behavior.

“We have an internal memo dated November 4, 2011 that shows FMC knew their products put patients at a much higher risk of catastrophic events including stroke, cardiac arrest and other life-threatening complications,” said Berman. “We intend to prove that rather than informing the FDA and seeking guidance, the company continued to aggressively market products it knew would put thousands of dialysis patients at risk.”

The memo also included instructions for FMC clinics designed to reduce the risk of life-threatening complications.

“We know that FMC thought the risks associated with its products were very serious, because it provided very clear advice to its own clinics on how to mitigate the issues,” said Mr. Berman. “In a stunning failure, however, FMC did not pass the word along to its other customers, a move that may have been good for short-term profits but risked thousands of patients’ lives.”

The FDA obtained a copy of the November 2011, internal memo and ordered a Class 1 recall, the most urgent type, of FMC’s GranuFlo product on March 29, 2012.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,521.83 -41.47 -0.25%
S&P 500 1,935.89 +5.22 0.27%
NASDAQ 4,380.1480 +10.3750 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs